LAVA Therapeutics NV LVTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if LVTX is a good fit for your portfolio.
News
-
LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results
-
Thinking about buying stock in Beyondspring, LAVA Therapeutics, Unicycive Therapeutics, Guardforce AI, or Infobird?
-
Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments
-
LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)
-
Thinking about buying stock in Societal CDMO, LAVA Therapeutics, Eastman Kodak, Brightspring Health Services, or Codexis?
-
Lava Therapeutics Shares Rise as Drug Set for Test With Merck's Keytruda
-
Stocks to Watch: Lululemon, Lava Therapeutics, Tilly's, Oncorus
Trading Information
- Previous Close Price
- $2.64
- Day Range
- $2.68–2.82
- 52-Week Range
- $1.13–6.47
- Bid/Ask
- $2.70 / $2.99
- Market Cap
- $71.77 Mil
- Volume/Avg
- 49,932 / 1.2 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 10.78
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
LAVA Therapeutics NV is a biotechnology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 37
- Website
- https://www.lavatherapeutics.com
Comparables
Valuation
|
Metric
|
LVTX
|
MRUS
|
IMTX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.40 | 7.29 | 3.33 |
Price/Sales | 10.78 | 52.76 | 13.48 |
Price/Cash Flow | — | — | — |
Price/Earnings
LVTX
MRUS
IMTX
Financial Strength
|
Metric
|
LVTX
|
MRUS
|
IMTX
|
|---|---|---|---|
Quick Ratio | 6.51 | 5.19 | 2.76 |
Current Ratio | 6.62 | 5.34 | 2.87 |
Interest Coverage | −192.52 | — | −132.38 |
Quick Ratio
LVTX
MRUS
IMTX
Profitability
|
Metric
|
LVTX
|
MRUS
|
IMTX
|
|---|---|---|---|
Return on Assets (Normalized) | −30.28% | −30.87% | −15.61% |
Return on Equity (Normalized) | −56.18% | −42.51% | −30.30% |
Return on Invested Capital (Normalized) | −54.28% | −44.25% | −33.80% |
Return on Assets
LVTX
MRUS
IMTX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Bhfkvmwhdx | Ptmg | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Xyxdfyxdt | Rmbfyzp | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Xrddfljby | Vfwnhr | $97.8 Bil | |
MRNA
| Moderna Inc | Hgryykgrt | Ldh | $41.3 Bil | |
ARGX
| argenx SE ADR | Mrtdqvf | Jnfpc | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Cwqsqts | Ycr | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Bdlxxbz | Pwdtnbl | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Hzvqtlf | Lbzxbrn | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Rykzjnvjy | Bmlpmjq | $12.5 Bil | |
INCY
| Incyte Corp | Wdlfmsyb | Bwswn | $11.6 Bil |